Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.61 |
| ▸ | MLYCD | O95822 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | FABP2 | P12104 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580868 | 0.89 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL3573066 | 0.87 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2MCHR1MLYCD | |
| SCHEMBL1386961 | 0.85 | TRPV1 (0.70) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL2987921 | 0.82 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL8668493 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL1368482 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL5201236 | 0.81 | ESRRG (0.50) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL1367702 | 0.80 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL1570073 | 0.80 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2CYP2D6GAA | |
| SCHEMBL96062 | 0.80 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2CYP2D6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | NPC1 6/4885RAB9A 3309/4885SMN1; SMN2 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.